COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection
Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network
Delaunay, Charlotte Laniece; Verdasca, Nuno; Monge, Susana; Domegan, Lisa; Seve, Noemie; Buda, Silke; Meijer, Adam; Lucaccioni, Heloise; Torrijos, Miriam Lopez; Mckenna, Adele; Enouf, Vincent; Duerrwald, Ralf; In't, Velt Eline; Laiglesia, Ma Angel de Valcarcel; Bennett, Charlene; Masse, Shirley; Erdwiens, Annika; Hooiveld, Mariette; Mlinaric, Ivan; Turi, Gergo [Túri, Gergő (népegészségügy), szerző] Epidemiológiai és Surveillance
Központ (SE / KSZE); Rodrigues, Ana Paula; Martinez-Baz, Ivan; Lazar, Mihaela; Latorre-Margalef, Neus; Borges, Vitor; Kaczmarek, Marlena; Bacci, Sabrina; Kissling, Esther ✉; European Primary Care VE Group [Kollaborációs szervezet]
Angol nyelvű Sokszerzős vagy csoportos szerzőségű szakcikk (Folyóiratcikk) Tudományos
Egészségbiztonság Nemzeti Laboratórium(RRF-2.3.1-21-2022-00006) Támogató: NKFIH
Szakterületek:
Vakcinák
We estimated the effectiveness of 2024/25 COVID-19 vaccination against medically attended
SARS-CoV-2 infection in Europe, among target groups. We included 3204 patients (8/139
cases vaccinated: 6%; 517/3065 controls vaccinated: 17%) from a multicentre, test-negative
design study at primary care level. Vaccine effectiveness was 66% (95% CI: 34-85)
overall, 73% (95% CI: 21-94) and 54% (95% CI: -3 to 83) in the first and second months
post-vaccination, respectively. Overall vaccine effectiveness was 67% (95% CI: 33-86)
among older adults (>= 60 or >= 65 years). This relatively high COVID-19 VE (compared
with previous seasons), as well as trends by time since vaccination, should be confirmed
with additional data, as sample size was low.
